Zorevunersen Trial Outcomes in Dravet Syndrome

An international clinical study led by University College London and Great Ormond Street Hospital reported early findings for zorevunersen, an investigational therapy evaluated in children and adolescents with Dravet syndrome. In the report’s description, investigators observed marked decreases in seizure frequency during treatment and subsequent follow-up, alongside early signals in broader patient-reported and functional domains. The same account describes an initial trial with follow-on extension studies. It also summarizes enrollment, dosing, tolerability, and additional trials underway.

The report describes 81 participants, ages two to 18 years, enrolled across the United Kingdom and the United States. Before treatment, the group was reported to have an average of 17 seizures per month. Zorevunersen was administered via lumbar puncture, with doses reported as high as 70 mg. The account adds that some participants received a single dose, while others received additional doses two or three months later during a six-month treatment period. Outcomes were followed further in extension studies that continued dosing and monitoring over time.

Seizure outcomes were summarized in the report as reductions reaching up to 91% among treated children with Dravet syndrome. For participants who received the 70 mg dose in the first stage, investigators reported that seizure frequency decreased by 59% to 91% during the first 20 months of the extension studies, compared with seizure counts recorded before treatment began. The report notes that multiple cohorts and dosing schedules were included in the early program, and it presents these figures as the main numerical range for the highest-dose group followed into the extension. Overall, the report portrays sizable seizure-frequency changes over months to years of observation.

The early studies were described as being primarily designed to assess safety and tolerability, with seizure frequency and additional domains monitored in parallel. In that context, the report characterizes most side effects as mild, without detailing a broader catalog of adverse events in the narrative summary. It also states that 75 children continued into extension studies, in which the medication was given every four months. Beyond seizure counts, the report notes improvements in quality of life over a three-year period and describes early evidence that thinking and behavior may have eased for some participants. Overall, the report frames tolerability and lived-experience measures as part of the observed follow-up picture.

Mechanistically, the report describes zorevunersen as aiming to increase production of a needed protein from the healthy copy of the SCN1A gene, to address reduced protein output associated with Dravet syndrome. As next steps, the same account states that a larger Phase 3 study is currently underway to further evaluate the therapy. Among UK sites, the report lists Great Ormond Street Hospital, Sheffield Children’s Hospital, Evelina London Children’s Hospital, and The Royal Hospital for Children in Glasgow. The report presents the Phase 3 launch as a continuation of the early-phase program described in the initial and extension studies.